Mohammed Mohiuddin

Summary

Affiliation: Geisinger Medical Center
Country: USA

Publications

  1. ncbi request reprint Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study
    Vincenzo Valentini
    Department of Radiation Therapy, Universita Cattolica del Sacro Cuore, Rome, Italy
    Int J Radiat Oncol Biol Phys 64:1129-39. 2006
  2. ncbi request reprint Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012
    Mohammed Mohiuddin
    Geisinger Cancer Institute, Wilkes Barre, PA 18711, USA
    J Clin Oncol 24:650-5. 2006
  3. doi request reprint Future directions in neoadjuvant therapy of rectal cancer: maximizing pathological complete response rates
    Mohammed Mohiuddin
    Geisinger Cancer Institute, 1000 E Mountain Blvd, Wilkes Barre, PA 18711, USA
    Cancer Treat Rev 35:547-52. 2009
  4. doi request reprint Management of rectal cancer: short- vs. long-course preoperative radiation
    Mohammed Mohiuddin
    Geisinger Cancer Institute, Wilkes Barre, PA, USA
    Int J Radiat Oncol Biol Phys 72:636-43. 2008
  5. ncbi request reprint Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers
    Mahesh Kudrimoti
    Department of Radiation Medicine, University of Kentucky Medical Center, Lexington, 40536 0293, USA
    J Ky Med Assoc 105:18-22. 2007
  6. ncbi request reprint Long-term results of reirradiation for patients with recurrent rectal carcinoma
    Mohammed Mohiuddin
    Department of Radiation Medicine, University of Kentucky Medical Center, Lexington 40536 0293, USA
    Cancer 95:1144-50. 2002
  7. doi request reprint Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells
    Mohammed Momin Shareef
    Weis Center for Research, Geisinger Clinic, Danville, PA, USA
    Mol Cancer Res 6:89-98. 2008
  8. doi request reprint ACR Appropriateness Criteria on resectable rectal cancer: expert panel on radiation oncology--rectal/anal cancer
    W Warren Suh
    Department of Radiation Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA 02459, USA
    Int J Radiat Oncol Biol Phys 70:1427-30. 2008
  9. ncbi request reprint Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm
    William F Regine
    Department of Radiation Oncology, University of Maryland, Baltimore, MD, USA
    Int J Radiat Oncol Biol Phys 68:172-7. 2007
  10. ncbi request reprint Spatially fractionated GRID radiation treatment of advanced neck disease associated with head and neck cancer
    Jeniffer L Huhn
    University of Kentucky, 800 Rose St N15, Lexington, KY 40536, USA
    Technol Cancer Res Treat 5:607-12. 2006

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study
    Vincenzo Valentini
    Department of Radiation Therapy, Universita Cattolica del Sacro Cuore, Rome, Italy
    Int J Radiat Oncol Biol Phys 64:1129-39. 2006
    ....
  2. ncbi request reprint Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012
    Mohammed Mohiuddin
    Geisinger Cancer Institute, Wilkes Barre, PA 18711, USA
    J Clin Oncol 24:650-5. 2006
    ..To evaluate the rate of pathologic complete response and toxicity of neoadjuvant chemoradiation for advanced T3/T4 distal rectal cancers in a randomized phase II study..
  3. doi request reprint Future directions in neoadjuvant therapy of rectal cancer: maximizing pathological complete response rates
    Mohammed Mohiuddin
    Geisinger Cancer Institute, 1000 E Mountain Blvd, Wilkes Barre, PA 18711, USA
    Cancer Treat Rev 35:547-52. 2009
    ..New paradigms in neoadjuvant therapy are therefore needed to further improve results of treatment. This review presents strategies for neoadjuvant therapy, with the potential to improve pCR rates and also survival of patients...
  4. doi request reprint Management of rectal cancer: short- vs. long-course preoperative radiation
    Mohammed Mohiuddin
    Geisinger Cancer Institute, Wilkes Barre, PA, USA
    Int J Radiat Oncol Biol Phys 72:636-43. 2008
    ....
  5. ncbi request reprint Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers
    Mahesh Kudrimoti
    Department of Radiation Medicine, University of Kentucky Medical Center, Lexington, 40536 0293, USA
    J Ky Med Assoc 105:18-22. 2007
    ..Pre-operative induction chemoradiotherapy has been used to downstage advanced rectal cancers. The variation in response rates is believed to be not only dependent on tumor size but also on the biological properties of individual tumors...
  6. ncbi request reprint Long-term results of reirradiation for patients with recurrent rectal carcinoma
    Mohammed Mohiuddin
    Department of Radiation Medicine, University of Kentucky Medical Center, Lexington 40536 0293, USA
    Cancer 95:1144-50. 2002
    ..The current study was conducted to assess the long-term results of reirradiation in patients with recurrent rectal carcinoma...
  7. doi request reprint Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells
    Mohammed Momin Shareef
    Weis Center for Research, Geisinger Clinic, Danville, PA, USA
    Mol Cancer Res 6:89-98. 2008
    ..Together, these results provide evidence for the lack of induction of P-glycoprotein expression by LDFRT, which has important implications in combinatorial cancer therapy, including the use of LDFRT as an adjuvant for chemotherapy...
  8. doi request reprint ACR Appropriateness Criteria on resectable rectal cancer: expert panel on radiation oncology--rectal/anal cancer
    W Warren Suh
    Department of Radiation Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA 02459, USA
    Int J Radiat Oncol Biol Phys 70:1427-30. 2008
    ..A summary of the major randomized clinical trials spanning the past several decades is provided...
  9. ncbi request reprint Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm
    William F Regine
    Department of Radiation Oncology, University of Maryland, Baltimore, MD, USA
    Int J Radiat Oncol Biol Phys 68:172-7. 2007
    ..To determine the maximum tolerated dose of upper abdominal low-dose fractionated radiotherapy (<1.0 Gy per fraction) given in combination with, and as a chemopotentiator for, gemcitabine...
  10. ncbi request reprint Spatially fractionated GRID radiation treatment of advanced neck disease associated with head and neck cancer
    Jeniffer L Huhn
    University of Kentucky, 800 Rose St N15, Lexington, KY 40536, USA
    Technol Cancer Res Treat 5:607-12. 2006
    ..It may improve pathologic complete response rates in those patients who undergo planned neck dissection, possibly leading to improved survival. In patients with inoperable bulky disease, addition of GRID enhances local-regional control...
  11. ncbi request reprint Long-term results of hyperfractionated radiation and high-dose intraarterial cisplatin for unresectable oropharyngeal carcinoma
    Paul M Spring
    Division of Otolaryngology Head and Neck Surgery, University of Kentucky Chandler Medical Center, Lexington, Kentucky, USA
    Cancer 104:1765-71. 2005
    ....
  12. ncbi request reprint Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: implications for endothelial apoptosis
    Sabapathi Sathishkumar
    Deptartment of Radiation Medicine, University of Kentucky, Lexington, Kentucky, USA
    Cancer Biol Ther 4:979-86. 2005
    ..Apparently, these changes are in the LDL-associated ceramide and may contribute to better tumor reduction after SFGRT, due to the ability of LDL-derived ceramide to sensitize endothelial cells for apoptosis...
  13. ncbi request reprint A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer
    Neil E Martin
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 10:5447-54. 2004
    ....
  14. ncbi request reprint Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm
    Susanne M Arnold
    Department of Medicine, University of Kentucky Markey Cancer Center, Lexington 40536, USA
    Int J Radiat Oncol Biol Phys 58:1411-7. 2004
    ..On the basis of the demonstrated synergy between chemotherapy and low-dose fractionated RT, a novel neoadjuvant therapy was designed using low-dose fractionated RT as a chemopotentiator for locally advanced SCCHN...
  15. ncbi request reprint Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck
    Paul M Spring
    Division of Otolaryngology, Department of Surgery, Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40536 0084, USA
    Cell Cycle 3:479-85. 2004
    ..Furthermore, the G(2)/M cell cycle arrest by TXT appears to be an important component of the enhanced apoptotic effect of TXT + LDFRT combined treatment...
  16. ncbi request reprint Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines
    Swatee Dey
    Department of Radiation Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky 40536, USA
    Clin Cancer Res 9:1557-65. 2003
    ..These findings strongly suggest that LDFRT (at these doses, HRS phenomenon is observed) can be used in combination with Paclitaxel to overcome the antiapoptotic effects of BCL-2 and nuclear factor kappa B...
  17. ncbi request reprint The impact of TNF-alpha induction on therapeutic efficacy following high dose spatially fractionated (GRID) radiation
    Sabapathi Sathishkumar
    University of Kentucky, Department of Radiation Medicine, 800 Rose Street, Lexington, KY 40536 0293, USA
    Technol Cancer Res Treat 1:141-7. 2002
    ..Complete tumor response strongly correlated with the induction of TNF-alpha levels in the serum...
  18. ncbi request reprint A phase II study of concomitant hyperfractionated radiation therapy and double dose intra-arterial cisplatin for squamous cell carcinoma of the head and neck
    William F Regine
    University of Kentucky, Department of Radiation Medicine, 800 Rose Street, Lexington, KY 40536 0293, USA
    Technol Cancer Res Treat 1:133-40. 2002
    ..Future investigation of this novel treatment strategy utilizing modern angiographic catheter/microcatherter technology will involve a single dose of IA cisplatin with HFX-RT and dose intensification using neoadjuvant therapy...
  19. ncbi request reprint Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study
    Mohammed Mohiuddin
    Department of Radiation Medicine, University of Kentucky, Lexington 40536 0293, USA
    Cancer J 8:255-62. 2002
    ..A phase I/II study was undertaken to establish the maximum tolerated dose of infusional gemcitabine when combined with radiation therapy in advanced gastrointestinal malignancies and to assess the response to treatment...
  20. ncbi request reprint Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells
    Meraj Mohiuddin
    Department of Radiation Medicine, University of Kentucky Medical Center, Lexington 40536 0293, USA
    Anticancer Res 22:825-30. 2002
    ..This study was undertaken to evaluate the impact of wild-type or mutant p53 status on the synergistic effects of 5-Fluorouracil (5-FU) and radiation (XRT) in pancreatic tumors...